Soligenix, Inc.

NasdaqCM:SNGX Voorraadrapport

Marktkapitalisatie: US$8.8m

Soligenix Toekomstige groei

Future criteriumcontroles 2/6

Soligenix's earnings are forecast to decline at 11% per annum while its annual revenue is expected to grow at 27.1% per year. EPS is expected to grow by 57.3% per annum.

Belangrijke informatie

-11.0%

Groei van de winst

57.3%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei27.1%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt03 Oct 2024

Recente toekomstige groei-updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Winst- en omzetgroeiprognoses

NasdaqCM:SNGX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20261-9N/AN/A2
12/31/20251-9N/AN/A2
12/31/20241-8N/AN/A2
6/30/20240-7-8-8N/A
3/31/20241-7-8-8N/A
12/31/20231-6-9-9N/A
9/30/20231-8-10-10N/A
6/30/20231-10-11-11N/A
3/31/20231-10-12-12N/A
12/31/20221-14-13-13N/A
9/30/20221-15-12-12N/A
6/30/20221-15-12-12N/A
3/31/20221-15-11-11N/A
12/31/20211-13-12-12N/A
9/30/20211-13-13-13N/A
6/30/20211-12-13-13N/A
3/31/20212-12-13-13N/A
12/31/20202-18-11-11N/A
9/30/20203-15-10-10N/A
6/30/20203-16-9-9N/A
3/31/20204-15-8-8N/A
12/31/20195-9-8-8N/A
9/30/20195-10-8-8N/A
6/30/20195-9-6-6N/A
3/31/20195-8-8-8N/A
12/31/20185-9-7-7N/A
9/30/20186-8-7-7N/A
6/30/20186-7-7-7N/A
3/31/20185-8N/A-6N/A
12/31/20175-7N/A-7N/A
9/30/20176-5N/A-6N/A
6/30/20177-6N/A-6N/A
3/31/20179-4N/A-6N/A
12/31/201610-3N/A-5N/A
9/30/201612-5N/A-5N/A
6/30/201613-1N/A-4N/A
3/31/201611-4N/A-5N/A
12/31/20159-8N/A-5N/A
9/30/20158-4N/A-4N/A
6/30/20157-11N/A-5N/A
3/31/20157-8N/A-4N/A
12/31/20147-7N/A-2N/A
9/30/20146-8N/A-3N/A
6/30/20144-10N/A-4N/A
3/31/20143-12N/A-4N/A
12/31/20133-10N/A-4N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: SNGX is forecast to remain unprofitable over the next 3 years.

Winst versus markt: SNGX is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: SNGX is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: SNGX's revenue (27.1% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: SNGX's revenue (27.1% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if SNGX's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven